Proteon Therapeutics Inc. (PRTO) Earns Buy Rating from Analysts at HC Wainwright
HC Wainwright began coverage on shares of Proteon Therapeutics Inc. (NASDAQ:PRTO) in a note issued to investors on Thursday. The firm set a “buy” rating on the biopharmaceutical company’s stock.
Separately, Zacks Investment Research raised Proteon Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 20th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $21.50.
Shares of Proteon Therapeutics (NASDAQ:PRTO) opened at 8.75 on Thursday. Proteon Therapeutics has a 52-week low of $4.90 and a 52-week high of $17.76. The company’s 50 day moving average price is $9.10 and its 200 day moving average price is $7.91. The firm’s market capitalization is $145.09 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/proteon-therapeutics-inc-prto-earns-buy-rating-from-analysts-at-hc-wainwright.html
Proteon Therapeutics (NASDAQ:PRTO) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.43) by $0.05. Analysts forecast that Proteon Therapeutics will post ($1.87) earnings per share for the current year.
Hedge funds have recently added to or reduced their stakes in the stock. Paloma Partners Management Co acquired a new stake in Proteon Therapeutics during the second quarter worth about $234,000. Deerfield Management Co. raised its stake in Proteon Therapeutics by 22.7% in the second quarter. Deerfield Management Co. now owns 1,552,031 shares of the biopharmaceutical company’s stock worth $12,463,000 after buying an additional 286,688 shares during the period. Bridgeway Capital Management Inc. raised its stake in Proteon Therapeutics by 211.2% in the second quarter. Bridgeway Capital Management Inc. now owns 36,835 shares of the biopharmaceutical company’s stock worth $296,000 after buying an additional 25,000 shares during the period. TFS Capital LLC acquired a new stake in Proteon Therapeutics during the second quarter worth about $206,000. Finally, Geode Capital Management LLC raised its stake in Proteon Therapeutics by 6.3% in the first quarter. Geode Capital Management LLC now owns 45,412 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 2,685 shares during the period. 51.54% of the stock is currently owned by hedge funds and other institutional investors.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.